SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner
SOD Sciences names Vivos Therapeutics a strategic investor and partner in the ReBalU Primed Cell Test.
Related stories
Toggle Holdings shares indicated for sale
L impact | EQUITY | Oct 30, 2026, 12:02 AM UTC
South Korea’s Kospi Opens 3.0% Lower at 5760.35
M impact | EQUITY | Oct 30, 2026, 12:01 AM UTC
Nikkei Opens 0.5% Lower at 64,344.37
The Nikkei Stock Average opened 0.5% lower, dragged by electronics and metals stocks.
M impact | EQUITY | Oct 30, 2026, 12:01 AM UTC
SK Hynix shares fall 5%
M impact | EQUITY | Oct 30, 2026, 12:00 AM UTC
US stock futures decline
L impact | EQUITY | Oct 30, 2026, 12:00 AM UTC
Origin Energy Q1 APLNG Revenue Jumps on Higher Prices and Data Centre Demand
M impact | EQUITY | Oct 30, 2026, 12:00 AM UTC